Flubromazolam

Flubromazolam is a synthetic triazolobenzodiazepine related to alprazolam, triazolam and flubromazepam. It has never been approved as a medicine and is known primarily as a designer benzodiazepine. The compound is notable for strong and prolonged sedative effects, with reports of substantial memory impairment lasting beyond the period of obvious sedation. Clinical and forensic reports have documented severe intoxications, including coma and deaths involving other depressants.

Chemistry and history

Flubromazolam combines a triazolobenzodiazepine ring system with bromine and fluorine substituents. It is structurally related to flubromazepam, but the additional fused triazole ring changes the compound’s pharmacological profile. It was first identified in seized tablets in Sweden in 2014, including products labelled as alprazolam.

Flubromazolam has appeared in tablets, powders and liquids, sometimes in counterfeit pharmaceutical products. The WHO reviewed it in 2020 because of its high potency, long-lasting central nervous system depression and increasing reports of non-medical use.

Pharmacology

Flubromazolam acts as a positive allosteric modulator at the benzodiazepine site of the GABA_A receptor. It enhances GABA-mediated inhibition and produces the sedative, anxiolytic, hypnotic and muscle-relaxant effects associated with benzodiazepines.

Its long-lasting effects are a particular concern. In a single-participant pharmacokinetic observation reviewed by WHO, sedation persisted for more than ten hours and partial amnesia lasted beyond 24 hours. Repeated peaks in serum concentration were also observed, suggesting that its effects may recur after an apparent period of improvement (WHO critical review, 2020).

Subjective effects

The PsychonautWiki profile of flubromazolam describes strong hypnotic and sedative effects, with users also reporting anxiety relief, muscle relaxation and pronounced memory impairment. The available accounts are anecdotal, but the prolonged sedation they describe is consistent with the pharmacokinetic observations reviewed by WHO.

Physical effects

Heavy sedation is a recurring feature. People may become markedly drowsy, unsteady or difficult to rouse. Motor coordination and reaction time can be impaired, and severe intoxication may progress to stupor or coma.

Cognitive effects

Amnesia is one of the most frequently described effects. Some reports describe incomplete memory formation during the period of intoxication, while others mention confusion and disinhibition. Anxiety suppression and muscle relaxation are also reported. The long duration means that cognitive impairment may continue after the person feels more alert.

Clinical intoxication

The WHO review summarised reports of 21 non-fatal and 11 fatal intoxications involving flubromazolam. Patients commonly presented with severe drowsiness or coma, and symptoms could persist for many hours because of the compound’s long-lasting effects. Some patients required intensive or critical care.

Flumazenil, a benzodiazepine receptor antagonist, has been used in some cases to reverse acute symptoms. However, the long persistence of flubromazolam means that sedation can recur after the antagonist wears off. Flumazenil also carries seizure risks in people with benzodiazepine dependence or certain co-ingestants, so its use requires specialist assessment.

Flubromazolam has also been detected in impaired-driving cases and post-mortem toxicology. Many deaths involved other substances, including opioids and additional sedatives, which complicates attribution. A study of nine flualprazolam deaths and wider forensic reviews show how often novel benzodiazepines appear in mixed-drug cases, although those findings should not be transferred directly to flubromazolam.

Dependence and safety

No controlled studies have established the dependence potential of flubromazolam. Online reports describe tolerance, loss of control over repeated use and severe withdrawal symptoms. These reports are anecdotal, but dependence is biologically plausible given its activity at the benzodiazepine site.

Combining flubromazolam with opioids, alcohol, barbiturates or other central nervous system depressants can intensify sedation and increase the risk of respiratory compromise. Abrupt discontinuation after regular use can cause dangerous withdrawal, including seizures. Its prolonged action and uncertain contents in counterfeit products make intoxication difficult to assess from appearance alone.

Related compounds

Flubromazolam is related to Flubromazepam, Alprazolam and Triazolam. Despite the similar names, flubromazolam and flubromazepam are different compounds with distinct structures and pharmacological profiles.